Septic Shock
Conditions
Brief summary
With a prevalence of more than 15% in ICU, septic shock today represents a real public health problem and remains the leading cause of mortality in ICU. Undernutrition is characterized by an alteration of the body composition and in particular by a loss of muscle mass. In intensive care, there are indirect elements suggesting a link between loss of muscle mass and prognosis. Muscle mass results from a balance between the pathway of proteolysis and that of protein synthesis, depending on many factors, not one of the most important are insulin. The protein PTP1B (Protein Tyrosine Phosphatase 1B), by the dephosphorylation of its numerous substrates, constitutes an endogenous regulator of numerous intracellular signaling pathways, including that of insulin. PTP1B could play a role in the protein synthesis abnormalities observed during sepsis leading clinically to impaired body composition including muscle body mass. Therefore, we propose to study the association between PTP1B and loss of muscle mass in patients in sepsis in resuscitation. The intestinal barrier plays an essential role in protecting against microbial luminal flora and the phenomenon of bacterial translocation. Zonulin is one of the major regulators of tight junctions, important actors in the intestinal barrier function. The increase in plasma zonulin levels, greater than 0.6 ng / mg, is directly correlated with increased intestinal permeability (16). However, elevation of plasma zonulin has never been evaluated in septic resuscitation patients. This is why we propose the evaluation of the association between plasma zonulin and the loss of muscle mass in these resuscitation patients.
Interventions
* D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube * D4 zonulin
* D1 * D4
* D1 * D4
Sponsors
Study design
Eligibility
Inclusion criteria
* Septic shock or severe sepsis * Age \> 18 years old * Affiliation to a social security system * Information and consent. If patient cannot give his consent, an emergency consent will be sign by trusted person * Contraception for woman, of childbearing age
Exclusion criteria
* Pregnancy or breastfeeding * Prisoners * Patient with pacemaker or defibrillator * patient participating to a clinical trial with the same primary outcome
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PTP1B analysis | Day 1 | 1 PAXgene tube (2,5 ml) will be used. RNA extraction will be done with a PAXgene Blood RNA System kit. |
| Muscular composition | Day 1 | Muscular composition will be measured by muscular echography with a 2B mode on D1 and D4 from the admission.T |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intestinal permeability | Day 1 | 1 tube of 5 ml Aprotinin will be taken on D1 and D4 to determine the expression of plasma zonulin. The concentration will be assayed by ELISA using a commercial kit (MyBiosource, USA). |
| Body composition | Day 1 | Body composition will be measured by impedancemetry on D1 and D4 |
Countries
France
Contacts
University Hospital, Rouen